CK LIFE SCIENCES(00775): Positive results achieved in the mid-term analysis of the Phase IIb study of Halneuron in treating chemotherapy-induced neuropathic pain.
Changjiang Life Sciences Technology (00775) announces the latest developments regarding the company's investment in Dogwood Therapeutics, Inc.
CK LIFE SCIENCES (00775) announces the latest progress regarding its investment in Dogwood Therapeutics, Inc. (Dogwood). On December 22, 2025, Dogwood announced positive results from the mid-term analysis of 97 treated patients in the Phase 2b study of Halneuron for chemotherapy-induced neuropathic pain (CINP). After reviewing the treatment data of non-blinded patients in the Phase 2b trial, the conclusion was reached that there was a difference in pain improvement between patients receiving Halneuron treatment and those receiving placebo treatment in the four-week study period.
Dogwood stated that the preliminary evidence of the effectiveness of Halneuron treatment is promising. Based on the mid-term analysis group where patients had an average duration of 5 years of CINP and 67% of patients meeting the inclusion criteria were concurrently receiving stable doses of other chronic pain medications including pregabalin, gabapentin, duloxetine, and opioids. Additionally, the overall dropout rate of the study was approximately 4.4%, much lower than the dropout rates of other FDA-approved chronic pain medications. Although still in the blinded phase, Dogwood believes that these findings once again demonstrate the encouraging safety and tolerability of Halneuron observed in previous clinical trials.
Based on the current recruitment rate and mid-term evaluation results of the Phase 2b trial, Dogwood still anticipates preliminary results by the third quarter of 2026. The current study is expected to provide approximately 80% to 85% statistical power to detect treatment differences of Halneuron.
Dogwood is registered in Delaware and listed on the Nasdaq Capital Market (stock code: DWTX). It is a development-stage biopharmaceutical company focused on developing new drugs for pain relief and neurological symptoms. The company currently holds about 83% indirect equity in Dogwood.
Related Articles

HK Stock Market Move | ZJLD(06979) rose by more than 4% again, the company claims it is to ensure the healthy operation of the market and some regions will temporarily stop promoting Big Zhen, a marketing campaign.

HK Stock Market Move | TOPSPORTS(06110) fell nearly 5% in the third quarter, with total sales in retail and wholesale businesses decreasing significantly on a year-on-year basis.

HK Stock Market Move | CSPC PHARMA (01093) rose more than 4% as Chairman Cai Dongchen increased his holdings. SYH2085 tablets have been approved for clinical trials in China.
HK Stock Market Move | ZJLD(06979) rose by more than 4% again, the company claims it is to ensure the healthy operation of the market and some regions will temporarily stop promoting Big Zhen, a marketing campaign.

HK Stock Market Move | TOPSPORTS(06110) fell nearly 5% in the third quarter, with total sales in retail and wholesale businesses decreasing significantly on a year-on-year basis.

HK Stock Market Move | CSPC PHARMA (01093) rose more than 4% as Chairman Cai Dongchen increased his holdings. SYH2085 tablets have been approved for clinical trials in China.






